Strategies for Managing Anemia in Chronic Kidney Disease
Abstract
Anemia is a common complication in chronic kidney disease (CKD) and is associated with decreased quality of life, deteriorating kidney function, increased illness, higher mortality rates, and elevated healthcare costs. Management of CKD-related anemia aims to enhance renal function (when feasible) and bolster red blood cell production. Anemia in chronic kidney disease (CKD) stems from a variety of factors, including reduced erythropoietin (EPO) production, inadequate iron availability or functionality, and inflammation leading to heightened levels of hepcidin, among other causes. Typical treatment for CKD-related anemia involves administering oral or intravenous iron supplements in conjunction with erythropoiesis-stimulating agents (ESAs). Over the past decade, erythropoiesis-stimulating agents (ESAs) have proven effective in boosting hemoglobin (Hb) levels for many patients. However, concerns about their safety, particularly regarding increased cardiovascular risk—especially at high doses and in hyporesponsive patients—have emerged. As a result, there's been a shift towards adopting more cautious Hb targets. Iron deficiency is widespread among CKD patients, particularly in those not undergoing dialysis. While iron supplementation has traditionally been used to support anemia management, there's growing recognition of the potential benefits of intravenous iron therapy, especially in the context of heart failure. HIF prolyl hydroxylase inhibitors are promising new drugs being clinically evaluated as alternatives to ESAs for anemia treatment in CKD patients. Initial data suggest they effectively boost endogenous erythropoietin production with potential benefits like lower peak concentrations, efficacy in inflamed patients, and improved iron utilization. However, further research is needed to confirm their safety and efficacy in the long term use.
Keywords: anemia, chronic kidney disease, erythropoiesis-stimulating agents, iron, HIF-prolyl-hydroxylase inhibitors
Keywords:
anemia, chronic kidney disease, erythropoiesis-stimulating agents, iron, HIF-prolyl-hydroxylase inhibitorsDOI
https://doi.org/10.22270/jddt.v14i4.6501References
Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne). 2021;8:642296. https://doi.org/10.3389/fmed.2021.642296 PMid:33842503 PMCid:PMC8032930
Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5-37.
Shaikh H, Hashmi MF, Aeddula NR. Anemia of Chronic Renal Disease. [Updated 2023 Feb 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943. https://doi.org/10.1371/journal.pone.0084943 PMid:24392162 PMCid:PMC3879360
Inker LA, Grams ME, Levey AS, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis. 2019;73(2):206-217. https://doi.org/10.1053/j.ajkd.2018.08.013 PMid:30348535 PMCid:PMC6348050
Del Vecchio L, Minutolo R. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? Journal of Clinical Medicine. 2021; 10(4):839. https://doi.org/10.3390/jcm10040839 PMid:33670704 PMCid:PMC7922992
Jelkmann W. Erythropoietin. Front Horm Res. 2016;47:115-27. https://doi.org/10.1159/000445174 PMid:27348128
Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013 Oct;40(5):302-9. https://doi.org/10.1159/000356193 PMid:24273483 PMCid:PMC3822280
Bock HA, Hirt-Minkowski P, Brünisholz M, et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant. 2008;23(1):301-308. https://doi.org/10.1093/ndt/gfm579 PMid:17890745
Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol. 2019;30(6):1037-1048. https://doi.org/10.1681/ASN.2018101007 PMid:31015255 PMCid:PMC6551773
Minutolo R, Garofalo C, Chiodini P, et al. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant. 2021;36(2):267-274. https://doi.org/10.1093/ndt/gfaa088 PMid:32829405
Schoener B, Borger J. Erythropoietin Stimulating Agents. [Updated 2023 Mar 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. (2015) 26:2578-87. https://doi.org/10.1681/ASN.2014080842 PMid:25736045 PMCid:PMC4587699
Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075-2084. https://doi.org/10.1093/ndt/gfu201 PMid:24891437 PMCid:PMC4209879
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-2448. https://doi.org/10.1056/NEJMoa0908355 PMid:19920054
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-668. https://doi.org/10.1093/eurheartj/ehu385 PMid:25176939 PMCid:PMC4359359
Van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. (2017) 136:1374-83. https://doi.org/10.1161/CIRCULATIONAHA.117.027497 PMid:28701470 PMCid:PMC5642327
Neiser S, Rentsch D, Dippon U, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals. 2015;28(4):615-635. https://doi.org/10.1007/s10534-015-9845-9 PMid:25801756
Rostoker G, Loridon C, Griuncelli M, et al. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study. EBioMedicine. 2019;39:461-471. https://doi.org/10.1016/j.ebiom.2018.11.020 PMid:30502056 PMCid:PMC6354439
Wagner M, Alam A, Zimmermann J, et al. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1573-1579. https://doi.org/10.2215/CJN.00380111 PMid:21734083
Macdougall IC, Bhandari S, White C, et al. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. J Am Soc Nephrol. 2020;31(5):1118-1127. https://doi.org/10.1681/ASN.2019090972 PMid:32253271 PMCid:PMC7217408
Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019;381(11):1001-1010. https://doi.org/10.1056/NEJMoa1813599 PMid:31340089
Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019;381(11):1011-1022. https://doi.org/10.1056/NEJMoa1901713 PMid:31340116
Zhang L, Hou J, Li J, Su SS, Xue S. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis. Aging (Albany NY). 2021;13(13):17914-17929. https://doi.org/10.18632/aging.203143 PMid:34115611 PMCid:PMC8312415
Haider MU, Furqan M, Mehmood Q. Daprodustat: A potential game-changer in renal anemia therapy-A perspective. Front Pharmacol. 2023;14:1249492. https://doi.org/10.3389/fphar.2023.1249492 PMid:37637409 PMCid:PMC10449327
Akizawa, T.; Nangaku, M.; Yonekawa, T.; Okuda, N.; Kawamatsu, S.; Onoue, T.; Endo, Y.; Hara, K.; Cobitz, A.R. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia. A randomized, double-blind, phase 3 trial. Clin. J. Am. Soc. Nephrol. 2020, 15, 1155-1165 https://doi.org/10.2215/CJN.16011219 PMid:32723804 PMCid:PMC7409739
Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021;384(17):1589-1600. https://doi.org/10.1056/NEJMoa2035938 PMid:33913637
Eckardt KU, Agarwal R, Aswad A, et al. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021;384(17):1601-1612. https://doi.org/10.1056/NEJMoa2025956 PMid:33913638
Nangaku M, Kondo K, Takabe S, et al. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. Ther Apher Dial. 2021;25(5):642-653. https://doi.org/10.1111/1744-9987.13611 PMid:33283981 PMCid:PMC8451920
Akizawa T, Macdougall IC, Berns JS, et al. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies [published correction appears in Am J Nephrol. 2019;50(2):160]. Am J Nephrol. 2019;49(4):271-280. https://doi.org/10.1159/000499111 PMid:30852574 PMCid:PMC6518868
Published
Abstract Display: 284 
PDF Downloads: 253 PDF Downloads: 17 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.